Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 27

Sort by

Sort Order Select

Journal Articles

Updated Report of a Phase I/II Multicenter Study of Forodesine, a Purine Nucleoside Phosphorylase Inhibitor, in Japanese Patients with Relapsed Peripheral T-Cell Lymphoma

Blood (2017) 130 (Supplement 1): 4075.

https://doi.org/10.1182/blood.V130.Suppl_1.4075.4075

Published: 2017

Journal Articles

Nelarabine in Combination with Etoposide and Cyclophosphamide Is Active in First Relapse of Childhood T-Acute Lymphocytic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LL)

Blood (2014) 124 (21): 795.

https://doi.org/10.1182/blood.V124.21.795.795

Published: 2014

Journal Articles

Acute Bone Marrow GvHD Is Associated With Delayed B Cell Neogenesis and Impaired Natural Antibody Response After Allogeneic Hematopoietic Stem Cell Transplantation

Angela Mensen, Korinna Jöhrens, Ioannis Anagnostopoulos, Sonya Demski, Christoph Ochs, Philipp Hemmati, MD, Giang Lam Vuong, MD, Kathrin Rieger, Olga Blau, Jörg Westermann, MD, Bernd Dörken, Carmen Scheibenbogen, Renate Arnold, Il-Kang Na

Blood (2013) 122 (21): 4605.

https://doi.org/10.1182/blood.V122.21.4605.4605

Published: 2013

Journal Articles

Correction of Immune and Enzyme Deficiency by Bone Marrow Transplant in PNP Deficient SCID

Vikramajit Singh, MRCP, Robert Wynn, MD, Denise Bonney, PhD, Stephen Hughes, MD, Kay Poulton, PhD, Helena Lee, PhD

Blood (2011) 118 (21): 4556.

https://doi.org/10.1182/blood.V118.21.4556.4556

Published: 2011

Journal Articles

Phase I Study of Forodesine (BCX1777), An Oral PNP Inhibitor In Patients with Relapsed or Refractory T/NK Malignancies.

Kunihiro Tsukasaki, MD, PhD, Michinori Ogura, MD, PhD, Hirokazu Nagai, MD, PhD, Jun Taguchi, MD, PhD, Tatsuya Suzuki, MD, PhD, Dai Maruyama, MD, PhD, Uchida Toshiki, MD, PhD, Takashi Oyama, MD, PhD, Tomomitsu Hotta, MD, PhD, Kensei Tobinai, MD, PhD

Blood (2010) 116 (21): 1796.

https://doi.org/10.1182/blood.V116.21.1796.1796

Published: 2010

Journal Articles

Forodesine, a Purine Nucleoside Phosphorylase (PNP) Inhibitor, Shows Clinical Activity In a Phase 2 Trial In Patients with Previously Treated Chronic Lymphocytic Leukemia (CLL) – Interim Analysis

Taimur Sher, MD, Jose Azar, MD, Stephen Spurgeon, MD, John Catalano, MBBS, FRACP, FRCPA, Richard R. Furman, MD, Miles Prince, MD, FRACP, FRCPA, Nancy L. Bartlett, MD, Simon Durrant, MBBS, FRCP, FRCPath, Ralph Boccia, MD, Aisha Masood, MD, Scott Lyman, MS, Jean Cantey-Kiser, William P Sheridan, MB, BS, Asher Chanan-Khan, MD

Blood (2010) 116 (21): 1397.

https://doi.org/10.1182/blood.V116.21.1397.1397

Published: 2010

Journal Articles

Influence of bone marrow stromal microenvironment on forodesine-induced responses in CLL primary cells

Kumudha Balakrishnan, Jan A. Burger, Maite P. Quiroga, Marina Henneberg, Mary L. Ayres, William G. Wierda, Varsha Gandhi

Blood (2010) 116 (7): 1083–1091.

https://doi.org/10.1182/blood-2009-10-246199

Published: 2010

Includes: Supplemental data

Journal Articles

Phase 2 and pharmacodynamic study of oral forodesine in patients with advanced, fludarabine-treated chronic lymphocytic leukemia

Kumudha Balakrishnan, Dushyant Verma, Susan O'Brien, John Michael Kilpatrick, Yuling Chen, Brenita F. Tyler, Susan Bickel, Shanta Bantia, Michael J. Keating, Hagop Kantarjian, Varsha Gandhi, Farhad Ravandi

Blood (2010) 116 (6): 886–892.

https://doi.org/10.1182/blood-2010-02-272039

Published: 2010

Journal Articles

Phase II, Single Center Study of Oral Forodesine in Patients with Advanced, Fludarabine-Treated Chronic Lymphocytic Leukemia (CLL).

Dushyant Verma, MD, FACP, Kumudha Balakrishnan, PhD, Susan O'Brien, MD, Deborah A. Thomas, MD, Alessandra Ferrajoli, MD, William G. Wierda, MD, PhD, Amit Verma, MD, Stefan Faderl, MD, Susan M Bickel, Shanta Bantia, PhD, Hagop M Kantarjian, MD, Michael J. Keating, MBBS, Varsha Gandhi, PhD, Farhad Ravandi, MD

Blood (2009) 114 (22): 2369.

https://doi.org/10.1182/blood.V114.22.2369.2369

Published: 2009

Journal Articles

In-Vitro Efficacy of the Deoxyguanoside Analogs Forodesine (BCX-1777) and ARA-G in Pediatric Acute Lymphoblastic Leukemia.

Irene Homminga, MD, Michel C. Zwaan, MD, PhD, Amel Seghouani, MD, Chantal Y. Manz, PhD, Shanta Bantia, PhD, Wilco Smits, Rob Pieters, MD, PhD, Jules P.P. Meijerink, PhD

Blood (2009) 114 (22): 2038.

https://doi.org/10.1182/blood.V114.22.2038.2038

Published: 2009

Journal Articles

Forodesine has high antitumor activity in chronic lymphocytic leukemia and activates p53-independent mitochondrial apoptosis by induction of p73 and BIM

Roberto Alonso, Mónica López-Guerra, Ramanda Upshaw, Shanta Bantia, Caroline Smal, Françoise Bontemps, Chantal Manz, Thomas Mehrling, Neus Villamor, Elias Campo, Emili Montserrat, Dolors Colomer

Blood (2009) 114 (8): 1563–1575.

https://doi.org/10.1182/blood-2009-02-207654

Published: 2009

Includes: Supplemental data

Journal Articles

A Phase II Study of the Purine Nucleoside Phosphorylase (PNP) Inhibitor RO5092888 (BCX-4208) in Patients with Moderate to Severe Chronic Plaque Psoriasis: Safety, Tolerability and Lymphocyte Effects

Joseph P Gomes, PharmD, MS, BCPS, Angela Georgy, Sharon Passe, Adrienne Farid, Shanta Bantia, PhD, Gerhard Wolff

Blood (2008) 112 (11): 2583.

https://doi.org/10.1182/blood.V112.11.2583.2583

Published: 2008

Journal Articles

BCX-4208 (RO5092888), a Purine Nucleoside Phosphorylase (PNP) Inhibitor, Is a Novel, Potent Orally Active Anti-T-Cell and B-Cell Agent.

Shanta Bantia, PhD, Cynthia Parker, Ramanda Upshaw, John Michael Kilpatrick, PhD, Amanda Cunningham, Jianwen Zhang, PhD, Pravin Kotian, PhD, Philip Morris, PhD, Pooran Chand, PhD, Yarlagadda S. Babu, PhD

Blood (2008) 112 (11): 1547.

https://doi.org/10.1182/blood.V112.11.1547.1547

Published: 2008

Journal Articles

Forodesine (Immucillin H, BCX-1777) Shows Activity on Mantle Cell Lymphoma Primary Cells

Andrea Rinaldi, Emilia Ceresa, Davide Rossi, Gianluca Gaidano, Shanta Bantia, PhD, Chantal Y. Manz, PhD, Carlo Catapano, Emanuele Zucca, Francesco Bertoni, MD

Blood (2008) 112 (11): 4997.

https://doi.org/10.1182/blood.V112.11.4997.4997

Published: 2008

Journal Articles

Response to Oral Forodesine in Refractory Cutaneous T-Cell Lymphoma: Interim Results of a Phase I/II Study.

Madeleine Duvic, MD, Andres Forero-Torres, MD, Francine Foss, MD, Elise Olsen, MD, Youn Kim, MD

Blood (2007) 110 (11): 122.

https://doi.org/10.1182/blood.V110.11.122.122

Published: 2007

Journal Articles

The Purine Nucleoside Phosphorylase Inhibitor Forodesine (BCX-1777) Is a Potent Cytotoxic Agent and Has Synergistic Activity with Bendamustine in Chronic Lymphocytic Leukemia (CLL) Irrespective of ZAP-70 Levels and p53 Status.

Roberto Alonso, PhD, Neus Villamor, MD, Ramanda Upshaw, BS, Shanta Bantia, PhD, Thomas Mehrling, MD, Elias Campo, MD, Emili Montserrat, MD, Dolors Colomer, PhD

Blood (2007) 110 (11): 3122.

https://doi.org/10.1182/blood.V110.11.3122.3122

Published: 2007

Journal Articles

Forodesine in Patients with Refractory/Relapsed T-ALL Can Induce Prolonged Stable Remission with Minimal Toxicity before and after Allogeneic Hematopoietic Stem Cell Transplantation.

Mattias Stelljes, MD, Joachim Kienast, MD, Björna Berning, MD, Nicola Gokbuget, MD, Dieter Hoelzer, MD, Gerda Silling, MD, Wolfgang E. Berdel, MD, Gary Van Houten Dahl, MD, Debra Schissel, RN, Molly Hemenway, PNP, Lia Gore, MD

Blood (2006) 108 (11): 5340.

https://doi.org/10.1182/blood.V108.11.5340.5340

Published: 2006

Journal Articles

Phase II Study of Forodesine, a PNP Inhibitor, in Patients with Relapsed or Refractory B-Lineage Acute Lymphoblastic Leukemia.

Ellen Ritchie, MD, Lia Gore, MD, Gail J. Roboz, MD, Eric Feldman, MD, Farhad Ravandi, MD, Richard Furman, MD

Blood (2006) 108 (11): 1881.

https://doi.org/10.1182/blood.V108.11.1881.1881

Published: 2006

Journal Articles

Forodesine IV (Bcx-1777) Is Clinically Active in Relapsed/Refractory T-Cell Leukemia: Results of a Phase II Study (Interim Report).

Richard R. Furman, MD, Lia Gore, MD, Farhad Ravandi, MD, Dieter Hoelzer, MD,PhD

Blood (2006) 108 (11): 1851.

https://doi.org/10.1182/blood.V108.11.1851.1851

Published: 2006

Journal Articles

Oral Forodesine (Bcx-1777) Is Clinically Active in Refractory Cutaneous T-Cell Lymphoma: Results of a Phase I/II Study.

Madeleine Duvic, MD, Andres Forero-Torres, MD, Francine Foss, MD, Elsie A. Olsen, MD, Youn Kim, MD

Blood (2006) 108 (11): 2467.

https://doi.org/10.1182/blood.V108.11.2467.2467

Published: 2006

NARROW

Updated Report of a Phase I/II Multicenter Study of Forodesine, a Purine Nucleoside Phosphorylase Inhibitor, in Japanese Patients with Relapsed Peripheral T-Cell Lymphoma

Nelarabine in Combination with Etoposide and Cyclophosphamide Is Active in First Relapse of Childhood T-Acute Lymphocytic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LL)

Acute Bone Marrow GvHD Is Associated With Delayed B Cell Neogenesis and Impaired Natural Antibody Response After Allogeneic Hematopoietic Stem Cell Transplantation

Correction of Immune and Enzyme Deficiency by Bone Marrow Transplant in PNP Deficient SCID

Phase I Study of Forodesine (BCX1777), An Oral PNP Inhibitor In Patients with Relapsed or Refractory T/NK Malignancies.

Forodesine, a Purine Nucleoside Phosphorylase (PNP) Inhibitor, Shows Clinical Activity In a Phase 2 Trial In Patients with Previously Treated Chronic Lymphocytic Leukemia (CLL) – Interim Analysis

Influence of bone marrow stromal microenvironment on forodesine-induced responses in CLL primary cells

Phase 2 and pharmacodynamic study of oral forodesine in patients with advanced, fludarabine-treated chronic lymphocytic leukemia

Phase II, Single Center Study of Oral Forodesine in Patients with Advanced, Fludarabine-Treated Chronic Lymphocytic Leukemia (CLL).

In-Vitro Efficacy of the Deoxyguanoside Analogs Forodesine (BCX-1777) and ARA-G in Pediatric Acute Lymphoblastic Leukemia.

Forodesine has high antitumor activity in chronic lymphocytic leukemia and activates p53-independent mitochondrial apoptosis by induction of p73 and BIM

A Phase II Study of the Purine Nucleoside Phosphorylase (PNP) Inhibitor RO5092888 (BCX-4208) in Patients with Moderate to Severe Chronic Plaque Psoriasis: Safety, Tolerability and Lymphocyte Effects

BCX-4208 (RO5092888), a Purine Nucleoside Phosphorylase (PNP) Inhibitor, Is a Novel, Potent Orally Active Anti-T-Cell and B-Cell Agent.

Forodesine (Immucillin H, BCX-1777) Shows Activity on Mantle Cell Lymphoma Primary Cells

Response to Oral Forodesine in Refractory Cutaneous T-Cell Lymphoma: Interim Results of a Phase I/II Study.

The Purine Nucleoside Phosphorylase Inhibitor Forodesine (BCX-1777) Is a Potent Cytotoxic Agent and Has Synergistic Activity with Bendamustine in Chronic Lymphocytic Leukemia (CLL) Irrespective of ZAP-70 Levels and p53 Status.

Forodesine in Patients with Refractory/Relapsed T-ALL Can Induce Prolonged Stable Remission with Minimal Toxicity before and after Allogeneic Hematopoietic Stem Cell Transplantation.

Phase II Study of Forodesine, a PNP Inhibitor, in Patients with Relapsed or Refractory B-Lineage Acute Lymphoblastic Leukemia.

Forodesine IV (Bcx-1777) Is Clinically Active in Relapsed/Refractory T-Cell Leukemia: Results of a Phase II Study (Interim Report).

Oral Forodesine (Bcx-1777) Is Clinically Active in Refractory Cutaneous T-Cell Lymphoma: Results of a Phase I/II Study.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only